>
Organization
ArQule, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed

News on ArQule, Inc.

... providing a clinical supply of Tecentriq. Derazantinib was licensed to Basilea from ArQule, in April 2018 for worldwide development and commercialization outside of China, Hong ...
... ArQule, Inc.'s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that ...
... Basilea Pharmaceutica has shared interim data from a registrational trial of ArQule-partnered cancer drug derazantinib. The oral FGFR kinase inhibitor achieved an objective response ...
... ArQule, Inc.'s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), today announced results ...
... ArQule, Inc. (Nasdaq: ARQL) today announced that it has been selected for inclusion in ...
... ArQule, Inc. (Nasdaq: ARQL) yesterday presented preliminary results from the Company's Phase 1 dose ...
... ArQule, Inc. (Nasdaq: ARQL) today announced that it will host a call to discuss ...
... ArQule, Inc. (Nasdaq: ARQL) today announced the presentation of clinical and preclinical data on ...
... ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc ...
... ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting clinical and preclinical ...
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/News/arqule-inc-o25429
  • https://relationshipscience.com/News/arqule-inc-o25429
Subscribe now for full coverage on ArQule, Inc.
Start My Free Trial